Personalised Medicine Implementation into Healthcare:
A Multistakeholder Approach for Translating Innovation into Clinical Practice
Christine Hasenauer¹
Hemma Bauer²
Wolfgang Ballensiefen¹
on behalf of the European Partnership for Personalised Medicine (EP PerMed) Consortium
¹ Deutsches Zentrum für Luft- und Raumfahrt e. V. (DLR), DLR Projektträger, Division Health, Bonn, Germany
² Federal Ministry of Women, Science and Research (BMFWF), Vienna, Austria
Corresponding Authors:
Dr Christine Hasenauer
Dr Wolfgang Ballensiefen
DLR Projektträger, Division Health
Heinrich-Konen-Str. 1, 53227 Bonn, Germany
Published: 23/10/2026
Abstract
Background
Personalised medicine has evolved from a largely research-driven concept into an increasingly important component of modern healthcare. Advances in genomics, molecular diagnostics, bioinformatics, artificial intelligence, and digital health technologies have enabled more precise approaches to disease prevention, diagnosis, and treatment. Despite considerable scientific progress, however, the implementation of personalised medicine within routine clinical practice remains uneven across Europe.
Objective
This article examines the principal barriers to implementing personalised medicine within healthcare systems and explores how coordinated multistakeholder collaboration can facilitate the translation of scientific innovation into everyday clinical care.
Discussion
Successful implementation of personalised medicine extends beyond technological innovation. It requires coordinated engagement of healthcare professionals, patients, citizens, medical societies, healthcare providers, researchers, regulators, and policymakers. Drawing upon the experience of the European Partnership for Personalised Medicine (EP PerMed), five complementary areas are identified as central to implementation: professional education, patient engagement, public health literacy, collaboration with medical societies, and cooperation between healthcare providers. Together, these domains create an integrated framework capable of supporting sustainable implementation across European healthcare systems.
Conclusions
The future of personalised medicine depends not only on scientific discovery but also on coordinated implementation strategies that integrate education, collaboration, governance, and public engagement. Multistakeholder partnerships provide an effective mechanism for translating innovation into equitable and sustainable healthcare across Europe.
Keywords
Personalised medicine; precision medicine; healthcare implementation; EP PerMed; multistakeholder collaboration; medical education; patient engagement; health literacy
Introduction
Personalised medicine has become one of the most significant developments in contemporary healthcare. Rather than applying uniform diagnostic and therapeutic strategies to all patients, personalised medicine seeks to tailor healthcare according to an individual's genetic profile, molecular characteristics, environmental exposures, and lifestyle factors.
During the past two decades, rapid advances in genomic sequencing, molecular pathology, advanced imaging, bioinformatics, artificial intelligence, and digital technologies have transformed personalised medicine from an emerging concept into an increasingly practical clinical reality. While initial applications focused primarily on oncology and rare diseases, personalised approaches are now expanding into numerous medical specialties.
Scientific progress alone, however, does not guarantee successful implementation. Integrating personalised medicine into routine healthcare requires changes in clinical practice, healthcare organisation, education, infrastructure, regulation, and public engagement. These challenges demand collaboration between multiple stakeholders operating across research, healthcare delivery, policy, education, and society.
From Scientific Innovation to Healthcare Implementation
Although personalised medicine has generated remarkable scientific advances, translating these discoveries into routine clinical care remains complex.
Healthcare systems must simultaneously address issues relating to clinical validation, reimbursement, digital infrastructure, ethical governance, data interoperability, workforce development, and equitable access to innovative technologies. The successful implementation of personalised medicine therefore depends not only on scientific excellence but also on organisational readiness.
The European Partnership for Personalised Medicine (EP PerMed) was established to address these implementation challenges by bringing together ministries, funding organisations, researchers, healthcare professionals, patient organisations, and policymakers across Europe. Building upon previous initiatives, including ICPerMed and ERA PerMed, the partnership promotes coordinated research, innovation, and implementation strategies capable of accelerating the adoption of personalised medicine within national healthcare systems.
A central concept underpinning the partnership is the "personalised medicine value continuum," recognising that research, innovation, implementation, and evaluation form a continuous and bidirectional process rather than isolated stages of development.
Education as the Foundation for Personalised Medicine
Healthcare professionals remain central to the successful implementation of personalised medicine.
The increasing complexity of molecular diagnostics, genomic testing, biomarker interpretation, and personalised therapeutic decision-making requires continuous professional development throughout medical careers. Educational programmes must therefore extend beyond specialist genetics to reach clinicians across all medical disciplines.
EP PerMed has supported this objective through dedicated educational initiatives, including the development of certified educational modules and implementation schools designed to promote knowledge exchange and interdisciplinary collaboration.
Future educational strategies should seek to integrate personalised medicine into undergraduate and postgraduate curricula while expanding access to flexible online learning opportunities tailored to specific clinical specialties. Such initiatives would help ensure that healthcare professionals possess the competencies necessary to incorporate personalised approaches into routine patient care.
Patients as Partners in Research and Care
Modern personalised medicine increasingly recognises patients as active participants rather than passive recipients of healthcare.
Patient organisations contribute valuable perspectives regarding research priorities, study design, dissemination of findings, and implementation of innovative healthcare approaches. Their involvement enhances the relevance of research while strengthening public trust and improving adoption of new technologies.
Although research funding increasingly supports patient participation, opportunities remain to expand educational resources enabling patient representatives to contribute more effectively throughout the research and implementation process.
Strengthening patient engagement therefore represents an important component of sustainable personalised medicine implementation.
Improving Public Health Literacy
Successful implementation also depends upon informed and engaged citizens.
Public understanding of personalised medicine influences acceptance of genomic testing, willingness to participate in research, confidence in data sharing, and adherence to increasingly complex diagnostic and therapeutic pathways.
Educational campaigns therefore play an essential role in promoting health literacy. Initiatives such as multilingual public surveys, educational podcasts, and broader communication strategies demonstrate how scientific information can be translated into accessible language for the general public.
In the longer term, incorporating concepts related to personalised medicine into school curricula may help prepare future generations for healthcare systems in which personalised approaches become increasingly routine.
The Role of Medical Societies
Medical societies occupy a unique position at the interface between scientific evidence and clinical practice.
They contribute to specialist education, continuing professional development, clinical guideline development, dissemination of research findings, and professional leadership. Consequently, their involvement is essential for integrating personalised medicine into everyday healthcare.
Closer collaboration between partnerships such as EP PerMed and European medical societies offers opportunities to strengthen educational activities, establish dedicated working groups, and harmonise approaches across specialties.
Such collaboration may also facilitate more rapid translation of research evidence into clinical guidelines and routine patient management.
Healthcare Networks and International Collaboration
Implementation of personalised medicine requires healthcare systems capable of sharing knowledge, experience, and successful clinical models.
International cooperation allows healthcare providers to exchange best practices, accelerate adoption of validated innovations, and reduce duplication of effort. Peer-to-peer learning initiatives and cross-border collaboration have already demonstrated value in disseminating successful personalised medicine approaches throughout Europe.
Examples such as molecular tumour boards illustrate how multidisciplinary collaboration enables complex genomic information to be translated into clinically meaningful treatment decisions while promoting consistent standards of care across institutions.
Discussion
The implementation of personalised medicine represents one of the greatest organisational challenges facing modern healthcare. Scientific innovation alone cannot transform patient care without parallel investment in education, infrastructure, governance, public engagement, and interdisciplinary collaboration.
The experience of EP PerMed illustrates the value of adopting a comprehensive multistakeholder approach that recognises implementation as a shared responsibility involving healthcare professionals, researchers, patients, policymakers, medical societies, and healthcare organisations.
Rather than addressing these components independently, successful implementation depends upon their coordinated integration within sustainable healthcare systems. Education strengthens professional competence, patient engagement enhances research relevance, public health literacy supports acceptance of innovation, medical societies facilitate clinical adoption, and healthcare networks accelerate dissemination of best practices.
Together, these elements create an environment in which personalised medicine can evolve from isolated innovation into routine clinical practice.
Conclusion
Personalised medicine has the potential to transform healthcare by delivering more precise, effective, and patient-centred diagnosis and treatment. Realising this potential, however, requires more than scientific discovery.
Sustainable implementation depends upon coordinated action across multiple sectors, including education, clinical practice, research, policy, healthcare management, and public engagement.
The multistakeholder framework promoted by the European Partnership for Personalised Medicine demonstrates how collaborative strategies can facilitate this transition. By strengthening cooperation between all participants in the healthcare ecosystem, Europe can accelerate the integration of personalised medicine into routine clinical practice while ensuring equitable, evidence-based, and sustainable healthcare for future generations.
Open Access & Copyright
© 2026 The Authors . Published by the European Medical Specialist Review (EMSR) under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0).
How to cite this article
Hasenauer C, Bauer H, Ballensiefen W. Personalised Medicine Implementation into Healthcare: A Multistakeholder Approach for Translating Innovation into Clinical Practice. European Medical Specialist Review. Published 23 October 2026. https://doi.org/10.67452/EMSR.2026.018